Published in J Clin Invest on December 01, 1989
Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg (1992) 2.96
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med (1995) 1.49
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A (1996) 1.34
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol (1997) 1.28
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer (1998) 1.28
Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg (2000) 1.22
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med (1994) 1.22
Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer (2009) 1.21
Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev (2007) 1.12
Salmonella typhi stimulation of human intestinal epithelial cells induces secretion of epithelial cell-derived interleukin-6. Infect Immun (1997) 1.12
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia (2007) 1.12
Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol (2006) 1.07
IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia (2014) 1.02
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer (2010) 1.02
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol (2011) 1.01
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Rational design of a receptor super-antagonist of human interleukin-6. EMBO J (1994) 0.94
Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest (1994) 0.94
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia (2010) 0.93
Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol (1993) 0.92
Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer (1993) 0.92
Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One (2012) 0.89
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
GP130 activation induces myeloma and collaborates with MYC. J Clin Invest (2014) 0.86
URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription. Cell Death Dis (2014) 0.85
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv (2011) 0.83
Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci (2009) 0.83
Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J Clin Invest (1993) 0.82
Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist (2011) 0.82
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One (2013) 0.81
Dilemmas in treating smoldering multiple myeloma. J Clin Oncol (2014) 0.81
Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol (1997) 0.80
Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm (1996) 0.80
HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma. J Cancer (2014) 0.80
The treatment of multiple myeloma--an important MRC trial. Br J Cancer (1994) 0.76
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean J Intern Med (2015) 0.76
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget (2017) 0.75
The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells. Oncotarget (2016) 0.75
Myelomagenesis: capturing early microenvironment changes. Semin Hematol (2011) 0.75
Association between Serum Levels of Interleukin-6 and Stage of Laryngeal Cancer. Iran J Otorhinolaryngol (2015) 0.75
Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case. Case Rep Oncol Med (2016) 0.75
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
Production of hybridoma growth factor by human monocytes. Eur J Immunol (1987) 7.99
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum (1988) 4.60
Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med (1987) 4.58
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Multiple actions of interleukin 6 within a cytokine network. Immunol Today (1988) 3.62
Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol (1988) 3.51
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol (1988) 2.24
Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol (1988) 1.70
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines. J Exp Med (1989) 1.28
Staging and kinetics of multiple myeloma. Semin Oncol (1986) 1.19
A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry (1985) 0.99
Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells. Clin Exp Immunol (1987) 0.86
Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982). Anticancer Res (1985) 0.85
Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol (2007) 3.05
Infectivity in mouse fibroblasts of polyoma DNA integrated into plasmid pBR322 or lambdoid phage DNA. Nature (1979) 2.92
Health and race in California. Am J Public Health (1971) 2.85
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol (1996) 2.21
An automated p-nitrophenylphosphate serum alkaline phosphatase procedure for the AutoAnalyzer. Clin Chem (1965) 2.14
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice. J Virol (1980) 1.85
Prioritising waiting lists. Health Trends (1990) 1.78
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood (1991) 1.73
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J Exp Med (1999) 1.67
Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci U S A (1997) 1.63
Fluorometry of plasma amino nitrogen, with use of fluorescamine. Clin Chem (1976) 1.61
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol (1989) 1.60
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A (1998) 1.55
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med (1996) 1.51
Lack of capillary recruitment in the brains of awake rats during hypercapnia. J Cereb Blood Flow Metab (1989) 1.51
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ (2000) 1.49
Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom (2010) 1.48
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol (1993) 1.47
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol (2000) 1.45
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
The cloned human DNA excision repair gene ERCC-1 fails to correct xeroderma pigmentosum complementation groups A through I. Mutat Res (1989) 1.42
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A (1998) 1.42
Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. Mutat Res (1999) 1.40
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
A temperature-sensitive disorder in basal transcription and DNA repair in humans. Nat Genet (2001) 1.37
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia (2000) 1.35
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood (2001) 1.34
Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr (2010) 1.34
Automated determination of serum glutamic oxaloacetic transaminase. Clin Chem (1966) 1.34
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol (1998) 1.33
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood (1992) 1.33
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum (1990) 1.32
Muc1 mucins on the cell surface are adhesion sites for Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol (2001) 1.32
RPC-5 column chromatography for the isolation of DNA fragments. Methods Enzymol (1980) 1.32
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
Splenomegaly and solitary spleen metastasis in solid tumors. Cancer (1987) 1.28
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood (1998) 1.27
A strong magnetic field around the supermassive black hole at the centre of the Galaxy. Nature (2013) 1.27
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
Clinicopathologic correlation of localized retinal pigment epithelium debridement. Invest Ophthalmol Vis Sci (1997) 1.24
Phage lambda DNA packaging, in vitro. J Supramol Struct (1974) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Interdependency of local capillary density, blood flow, and metabolism in rat brains. Am J Physiol (1986) 1.23
Thin film growth of Fe-based superconductors: from fundamental properties to functional devices. A comparative review. Rep Prog Phys (2014) 1.21
Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol (2000) 1.21
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene (2006) 1.21
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 1.20
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol (1999) 1.20
Tracking correlations of blood pressure levels in infancy. Pediatrics (1978) 1.19
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Complete nucleotide sequence of the cloned infectious genome of Junonia coenia densovirus reveals an organization unique among parvoviruses. Virology (1992) 1.19
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol (1992) 1.17
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol (1995) 1.16
Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood (1998) 1.16
Phage lambda receptor chromosomes for DNA fragments made with restriction endonuclease I of Bacillus amyloliquefaciens H. J Mol Biol (1979) 1.15
Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. Eur J Cancer (1980) 1.14
Retinal collateral vessel formation. Invest Ophthalmol (1971) 1.13
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood (1994) 1.13
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Evaluation of Acoustic Radiation Force Impulse (ARFI) imaging and contrast-enhanced ultrasound in renal tumors of unknown etiology in comparison to histological findings. Clin Hemorheol Microcirc (2009) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Transcription of sea urchin histone genes in Escherichia coli. Nucleic Acids Res (1981) 1.10
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood (1996) 1.10
Phage-types and susceptibility to 26 antibiotics of nosocomial strains of Acinetobacter isolated in Portugal. J Int Med Res (1984) 1.10
C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma (1998) 1.09
Determinants of choice and change of health insurance plan. Med Care (1971) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Microinjection of human cell extracts corrects xeroderma pigmentosum defect. EMBO J (1983) 1.09
Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw (1999) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08